Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Taking Atripla Three Days a Week Maintains Undetectable HIV Viral Load, Pilot Study Finds

Taking efavirenz/tenofovir/emtricitabine (Atripla) three days a week maintained an undetectable viral load for at least 24 weeks in people who were already virally suppressed for at least two years, according to a small, proof-of-concept study presented at ASM Microbe 2016 in Boston, Massachusetts.

Published
22 June 2016
From
The Body Pro
WHO confirms antiretroviral therapy reduces the risk of life-threatening HIV-related infections

Adults and children with HIV who start antiretroviral therapy (ART) as early as possible reduce their risk of developing serious HIV-related infections, according to new findings published in the journal Clinical Infectious Diseases on 15 June 2016.

Published
22 June 2016
From
World Health Organization
Investigational Integrase Inhibitor Bictegravir Safe and Effective Against HIV in Early Study

A new integrase inhibitor known as bictegravir (BIC, GS-9883) was found to be well tolerated and effective as HIV treatment in a 10-day monotherapy study, warranting further investigation of the drug, according to research presented at ASM Microbe 2016 in Boston, Massachusetts.

Published
21 June 2016
From
The Body
China offers free antiviral therapy for HIV/AIDS

Antiviral treatment should be recommended for all those with HIV/AIDS under China's newly revised guidelines, said an online notice issued by the National Health and Family Planning Commission on Wednesday.

Published
20 June 2016
From
Asia One
WHO releases second edition of Consolidated ARV guidelines

This edition updates the 2013 consolidated guidelines on the use of antiretroviral drugs following an extensive review of evidence and consultations in mid-2015, shared at the end of 2015, and now published in full in 2016. It is being published in a changing global context for HIV and for health more broadly.

Published
15 June 2016
From
World Health Organization
Fast Rebound After Treatment Interruption in 9 of 10 With Low HIV DNA Reservoir

Nine of 10 people with a cell-associated HIV DNA level below 100 copies/106 cells had an HIV RNA rebound within 12 weeks after antiretroviral therapy interruption. The 10th person maintained HIV RNA control without drugs for more than 48 weeks, according to a study published in AIDS.

Published
13 June 2016
From
The Body PRO
Less frequent CD4 and viral load monitoring safe for people doing well on ART

The frequency of routine monitoring for people treated with antiretrovirals with viral suppression can be safely reduced from every three months, to every six months, investigators from

Published
13 June 2016
By
Michael Carter
Big increases in proportion of HIV-positive people in US treated with ART and with viral suppression

The proportion of people living with HIV receiving care in the United States who accessed antiretroviral therapy (ART) and achieved viral suppression increased substantially between 2009 and

Published
10 June 2016
By
Michael Carter
Sub-type C infection does not increase the risk of virologic failure when people are taking tenofovir-containing first-line ART

There is no evidence that HIV-positive people with sub-type C infection have an increased risk of treatment failure when receiving tenofovir-containing regimens, investigators from the UK report in

Published
08 June 2016
By
Michael Carter
Frontier Biotech's Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial

Frontier Biotechnologies Inc. today reported that a phase 3 clinical trial (TALENT Study) of its lead product albuvirtide meets primary objective based on an interim analysis. The results demonstrated that once-weekly given albuvirtide plus ritonavir-boosted lopinavir was non-inferior to WHO-recommended second-line three-drug regimen (control) at 48-week in treatment experienced HIV-1 infected adults. In addition, patients administered with albuvirtide showed statistically better renal safety than those taking the control regimen containing tenofovir disoproxil fumarate.

Published
07 June 2016
From
Frontier Biotech press release
← First12345...419Next →

Filter by country